Shenzhen GuoHua Network Security Technology announced that its wholly-owned subsidiary, Shenzhen GuoHua Zhijian Pharmaceutical Technology Co., Ltd., plans to increase capital by 12.7186 million yuan for Hefei Tuorui Biotechnology Co., Ltd. After the capital increase, GuoHua Zhijian will hold 51% equity of Hefei Tuorui, and Hefei Tuorui will be included in the company's consolidated financial statements. Hefei Tuorui mainly engages in the research and development of Chemical Drugs. This capital increase aims to optimize and integrate the company's resources, deeply explore and expand business opportunities in the field of new quality productivity, foster new performance growth points for the company, and enhance the company's core competitiveness and sustainable operation capabilities. The funding for this capital increase comes from the company's own funds and will not affect the normal operation of the company's existing main business.